| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/22/2002 | WO2002064160A2 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 08/22/2002 | WO2002064151A1 Acrochordon alleviation |
| 08/22/2002 | WO2002064150A1 Whitening compositions containing ascomycete derived enzyme |
| 08/22/2002 | WO2002064142A1 Farnesyl protein transferase inhibitor combinations with antiestrogen agents |
| 08/22/2002 | WO2002064139A1 Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity |
| 08/22/2002 | WO2002064133A1 Preparations for controlling concentration in blood |
| 08/22/2002 | WO2002064132A2 Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| 08/22/2002 | WO2002064130A1 Proliferative activator receptor (ppar) compounds |
| 08/22/2002 | WO2002064128A1 Treatment of diseases characterized by excessive or insufficient cell death |
| 08/22/2002 | WO2002064127A1 Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
| 08/22/2002 | WO2002064121A1 Novel modified released formulation |
| 08/22/2002 | WO2002064118A1 Novel modified release formulation |
| 08/22/2002 | WO2002064114A1 Novel ophthalmic compositions |
| 08/22/2002 | WO2002064111A1 Vitamin/mineral complex |
| 08/22/2002 | WO2002064108A2 Delivery of biologically active agents |
| 08/22/2002 | WO2002064096A2 Methods of using pyrimidine-based antiviral agents |
| 08/22/2002 | WO2002064094A2 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
| 08/22/2002 | WO2002064087A2 Neurotherapeutic use of carboxypeptidase inhibitors |
| 08/22/2002 | WO2002064085A2 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
| 08/22/2002 | WO2002064065A2 Methods and apparatus for stenting comprising enhanced embolic protection, coupled with improved protection against restenosis and thrombus formation |
| 08/22/2002 | WO2002064046A2 A compound and method of treatment for fungal pathologies of the oral cavity |
| 08/22/2002 | WO2002064026A2 Treating pulmonary disorders with gaseous agent causing repletion of gsno |
| 08/22/2002 | WO2002064014A2 Endomural therapy |
| 08/22/2002 | WO2002063982A1 Composition and method for smoke detoxification |
| 08/22/2002 | WO2002063954A2 USE OF β-LACTAMASE INHIBITORS AS NEUROPROTECTANTS |
| 08/22/2002 | WO2002047534A3 Compositions and methods for the therapy and diagnosis of lung cancer |
| 08/22/2002 | WO2002045652A3 Tyrosine kinase inhibitors |
| 08/22/2002 | WO2002044159A3 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence |
| 08/22/2002 | WO2002040021A3 Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines |
| 08/22/2002 | WO2002040008A3 Treatment of sexual dysfunction with non peptide bombesin receptor antagonists |
| 08/22/2002 | WO2002033050A3 Methods and compositions for promoting the maturation of monocytes |
| 08/22/2002 | WO2002032893A3 Piperidine compounds as anti-allergic |
| 08/22/2002 | WO2002032862A3 Use of p38 inhibitors for the treatment of smoke inhalation |
| 08/22/2002 | WO2002024221A3 Notch receptor agonists and uses |
| 08/22/2002 | WO2002024204A3 Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter |
| 08/22/2002 | WO2002015959A3 Compounds and compositions for delivering active agents |
| 08/22/2002 | WO2002000233A3 Purging of cells using viruses |
| 08/22/2002 | WO2001085204A3 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
| 08/22/2002 | WO2001085203A3 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
| 08/22/2002 | WO2001072295A3 Compositions and methods for the therapy and diagnosis of lung cancer |
| 08/22/2002 | WO2001042506A9 T1 receptor-like ligand ii and uses thereof |
| 08/22/2002 | WO2000038706A9 Methods for treating cancer and for mediating chemotaxis of dendritic cells |
| 08/22/2002 | WO2000035423A9 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same |
| 08/22/2002 | WO2000032239A9 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 08/22/2002 | WO2000014200A9 Essential bacterial genes and their use |
| 08/22/2002 | WO2000011195A9 C-myc is activated by beta-catenin and tcf-4 |
| 08/22/2002 | US20020116272 Advertising strategy and motivational behavior modification method for weight loss |
| 08/22/2002 | US20020115848 IBD-associated microbial nucleic acid molecules |
| 08/22/2002 | US20020115843 Nucleotide sequences for use in the treatment of viral diseases, hypertension and coagulation defects |
| 08/22/2002 | US20020115728 Compositions and methods for treating cardiovascular disorders |
| 08/22/2002 | US20020115719 Control of microbial populations in the gastrointestinal tract of animals |
| 08/22/2002 | US20020115716 Oral low dose butyrate compositions |
| 08/22/2002 | US20020115710 Composition and method |
| 08/22/2002 | US20020115705 Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| 08/22/2002 | US20020115704 Treatment method |
| 08/22/2002 | US20020115703 Administering an alpha2-adrenoceptor antagonist or a pharmaceutically acceptable ester or salt thereof, such as atipamezole, analogs of idazoxan, and analogs of efaroxan. |
| 08/22/2002 | US20020115695 Combinations of a prostaglandin agonist and a HMG-CoA reductase inhibitor |
| 08/22/2002 | US20020115683 Treatment of anti-depression drug-induced sexual dysfunction with apomorphine |
| 08/22/2002 | US20020115681 Anticholinergics which have a long-lasting effect, such as glycopyrronium bromide, tiotropium bromide or an ester of bi-or tricyclic amino alcohol such as a nortropanol |
| 08/22/2002 | US20020115676 Therapy for andropause using estrogen agonists / antagonists and testosterone |
| 08/22/2002 | US20020115671 Inhibitors of p38-a kinase |
| 08/22/2002 | US20020115667 Treatment of disorders associated with glycolipid accumulation, such as Niemann-Pick Type C disease by administering an inhibitor of glucosylceramide synthesis, such as N-butyldeoxynojirimycin |
| 08/22/2002 | US20020115665 Contacting the calpain with an effective amount of an HIV protease inhibitor, |
| 08/22/2002 | US20020115661 Method for treating chronic obstructive pulmonary disease |
| 08/22/2002 | US20020115656 Administering 2-(1-(3-(5-Acetyl-3-(4-chloro-phenyl)-4,5,6,7-tetrahydro-pyrazolo-(4,3 -c)pyridin-1-yl)-2-hydroxy-propyl)-piperidin-4-ylamino)-benzonitrile for inhibiting cathepsins; for treating atopic diseases |
| 08/22/2002 | US20020115655 Calcium channel blockers |
| 08/22/2002 | US20020115649 Use of texaphyrins in macrophage-mediated disease |
| 08/22/2002 | US20020115646 Hair loss prevention |
| 08/22/2002 | US20020115644 Tetracycline compounds for treatment of Cryptosporidium parvum related disorders |
| 08/22/2002 | US20020115641 Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers |
| 08/22/2002 | US20020115635 Modulation of GSK-3beta activity and its different uses |
| 08/22/2002 | US20020115631 Human bad polypeptides, encoding nucleic acids and methods of use |
| 08/22/2002 | US20020115627 Phosphatonin-related gene and methods of use thereof |
| 08/22/2002 | US20020115626 Comparing the expression of the nucleic acid encoding an antileuko-protease polypeptide of a cell population to the expression of a nucleic acid encoding the same peptide in an inflammation positive reference profile; enzyme inhibitors |
| 08/22/2002 | US20020115624 Such as alpha-galactosylceramide and alpha-glucosylceramide; screening method to identify putative alpha-glycosylceramide molecules that can stimulate NKT cells through a CD1d mechanism; detecting a shift toward a Th1 response |
| 08/22/2002 | US20020115618 Comprising a cold compounded mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor, antioxidant and carrier; side effect reduction; partial recovery of neurological function in some cases |
| 08/22/2002 | US20020115613 Treatment of prostate cancer |
| 08/22/2002 | US20020115186 Peptide for use in the diagnosis, prevention, and treatment of inflammation, cancer, arteriosclerosis and degenerative defects |
| 08/22/2002 | US20020115176 Polypeptide for use in the diagnosis and treatment of asthma, and respiratory disorders |
| 08/22/2002 | US20020115167 Isolation of drosophila and human polynucleotides encoding PAR-1 kinase, polypeptides encoded by the polynucleotides and methods utilizing the polynucleotides and polypeptides |
| 08/22/2002 | US20020115166 Peptide for use in the treatment of pancreatic defects |
| 08/22/2002 | US20020115140 Nucleotide sequences coding preferential polypeptide for use in treatment of immmunological defects |
| 08/22/2002 | US20020115138 Nucleotide sequences coding transport protein for use in treat ment of tumors |
| 08/22/2002 | US20020115120 Controlling polypetide activity in cell; obtain cell, incubate with modulator, monitor gene expression and protein activity |
| 08/22/2002 | US20020115109 Compositions and methods for diagnosing/treating disease based on beta-catenin/transcription factor interactions |
| 08/22/2002 | US20020115081 Nucleotide sequences coding polypeptide for use in the the treatament of cardiovasculAR disorders |
| 08/22/2002 | US20020114847 Wound healing compound |
| 08/22/2002 | US20020114837 Galenic composition for low bioavailability medicaments |
| 08/22/2002 | US20020114835 Administering at a site biocompatible, biodegradable, biodegradable, controlled release formulation comprising a local anesthetic, being present in a concentration effective to induce a localized condition |
| 08/22/2002 | US20020114811 Contacting body fluid from mammal with antibody which binds to human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide under conditions sufficient to form antigen-antibody complex and detecting complex |
| 08/22/2002 | US20020114810 Diagnosis and treatment of malignant neoplasms statement as to federally sponsored research |
| 08/22/2002 | US20020114809 Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| 08/22/2002 | US20020114807 Administering drug comprising a substance that specifically recognizes extracellular domain of signal regulatory proteins and that inhibits functioning of pathologic myeloid cells |
| 08/22/2002 | US20020114803 Compositions and methods for enhancing receptor-mediated cellular internalization |
| 08/22/2002 | US20020114796 Wound healing agents comprising fibrinogen, fibrin, thrombin, transglutaminase, and serpin protease inhibitor which doesn not inhibit collagenase and elastase in blood plasma |
| 08/22/2002 | US20020114792 Alpha-2-macroglobulin therapies and drug screening methods for Alzheimer's disease |
| 08/22/2002 | US20020114789 Methods of controlling proliferation and differentiation of stem and progenitor cells |
| 08/22/2002 | US20020114781 Interleukin antagonists for suppressing autoimmune respone via reducing number of antigen-reactive lymphocytes; treatment of rheumatic diseases |
| 08/22/2002 | US20020114772 Methods of modulating hair growth |
| 08/22/2002 | DE10108215A1 Pharmazeutische Kombination von Antagonisten von Angiotensin II und Hemmern von Angiotensin II konvertierendem Enzym A pharmaceutical combination of antagonists of angiotensin II inhibitors and angiotensin II converting enzyme |